JPH0449277A - Novel substance cc12 - Google Patents
Novel substance cc12Info
- Publication number
- JPH0449277A JPH0449277A JP16066690A JP16066690A JPH0449277A JP H0449277 A JPH0449277 A JP H0449277A JP 16066690 A JP16066690 A JP 16066690A JP 16066690 A JP16066690 A JP 16066690A JP H0449277 A JPH0449277 A JP H0449277A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- streptomyces
- agar
- methanol
- novel substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 241000187747 Streptomyces Species 0.000 claims abstract description 9
- 241000187180 Streptomyces sp. Species 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 241000192125 Firmicutes Species 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 16
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000186361 Actinobacteria <class> Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710128742 Cytochrome b6-f complex iron-sulfur subunit 2 Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RUXHWBMJNBBYNL-UHFFFAOYSA-N 3-hydroxy-1,2-dihydropyrrol-5-one Chemical class OC1=CC(=O)NC1 RUXHWBMJNBBYNL-UHFFFAOYSA-N 0.000 description 1
- 101000775660 Anarhichas lupus Type-3 ice-structuring protein 1.5 Proteins 0.000 description 1
- 101000775628 Anarhichas lupus Type-3 ice-structuring protein 1.9 Proteins 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 101710128746 Cytochrome b6-f complex iron-sulfur subunit 1 Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101000643905 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Cytochrome b6-f complex iron-sulfur subunit 3 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101000775697 Pseudopleuronectes americanus Ice-structuring protein 3 Proteins 0.000 description 1
- 101000775692 Pseudopleuronectes americanus Ice-structuring protein 4 Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NJUISRMVIKYYCN-UHFFFAOYSA-N acetic acid;chloroform;methanol;hydrate Chemical compound O.OC.CC(O)=O.ClC(Cl)Cl NJUISRMVIKYYCN-UHFFFAOYSA-N 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000019646 color tone Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は抗菌性を有する新規物質CC12およびその製
造法に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a novel substance CC12 having antibacterial properties and a method for producing the same.
(従来の技術)
従来、テトラミン酸誘導体としては例えば、チランダマ
イシン(tirandamycin; No1te、M
、J、 etal、、 J、C,hem、soc、Pe
rkin TransI、85巻、1057−1065
頁(1980))が知られている。(Prior Art) Conventionally, as a tetramic acid derivative, for example, tyrandamycin (No1te, M
,J,etal,,J,C,hem,soc,Pe
rkin Trans I, vol. 85, 1057-1065
Page (1980)) is known.
(発明が解決しようとする課題)
本発明者らは、土壌から分離したストレプトミセス属に
属するストレプトミセス・エスピーSANK 6039
0株の培養物から、抗菌性を有する新規物質CC’12
が生産されることを見出して本発明を完成した。(Problems to be Solved by the Invention) The present inventors have discovered Streptomyces sp. SANK 6039, which belongs to the genus Streptomyces and was isolated from soil.
A new substance with antibacterial properties CC'12 was developed from a culture of 0 strains.
The present invention was completed by discovering that this can be produced.
(課題を解決するための手段)
本発明の新規物質CC12は下記の構造式および理化学
的性状を有する。(Means for Solving the Problems) The novel substance CC12 of the present invention has the following structural formula and physical and chemical properties.
1)構造式
2)外観; 無色粉末
3)融点; 161−166℃
4)比旋光度: [α]。+75.ド(c 1.0゜
メタノール中)
5)溶解性:
水、メタノール、エタノールに可溶、アセトンに微溶、
酢酸エチル、クロロホルム、ヘキサンに不溶。1) Structural formula 2) Appearance; Colorless powder 3) Melting point; 161-166°C 4) Specific optical rotation: [α]. +75. (c 1.0° in methanol) 5) Solubility: Soluble in water, methanol, ethanol, slightly soluble in acetone,
Insoluble in ethyl acetate, chloroform, and hexane.
6)薄層クロマトグラフィm:
■Rf値; 0.20
吸着剤ニジリカゲル60 F254 (商品名、メルク
社製)
展開溶剤;クロロホルム−メタノール−酢酸−水(8:
4:1:1)
■Rf値; 0.22
吸着剤ニジリカゲル60 F254 (商品名、メルク
社製)
展開溶剤;クロロホルム−メタノール−29%アンモニ
ア水(3:3:1)
7)高分解能マススペクトル(m/z):855.54
83 (M+H)”
8)元素分析:、(%)
実測値 C64,32、H8,37、N 6.36.0
20.00
計算値 C66,02、H8,72、N 6.55.0
18.71
9)分子式: C47H74N 401゜10)紫外
吸収スペクトル:λ、、、ax nm(E)■メタノー
ル中
207 (19500) 、245 (9900) 、
282 (10000)■0.01規定塩酸−メタノ
ール中
207 (18900) 、250 (6600) 、
282 (9900)■0.01規定水酸化ナトリウム
ーメタノール中208 (19900) 、245 (
9700) 、281 (9600)11)赤外吸収ス
ペクトルニジ。、xcm”−’臭化カリウム(KBr)
錠剤法で測定した赤外線吸収スペクトルは第1図に示す
通りである。6) Thin layer chromatography m: ■Rf value; 0.20 Adsorbent Nijiri Gel 60 F254 (trade name, manufactured by Merck & Co., Ltd.) Developing solvent: Chloroform-methanol-acetic acid-water (8:
4:1:1) ■Rf value: 0.22 Adsorbent Nijiri Kagel 60 F254 (trade name, manufactured by Merck & Co., Ltd.) Developing solvent: Chloroform-methanol-29% aqueous ammonia (3:3:1) 7) High-resolution mass spectrum (m/z):855.54
83 (M+H)" 8) Elemental analysis: (%) Actual value C64.32, H8.37, N 6.36.0
20.00 Calculated value C66.02, H8.72, N 6.55.0
18.71 9) Molecular formula: C47H74N 401°10) Ultraviolet absorption spectrum: λ,,, ax nm (E)■207 (19500), 245 (9900) in methanol,
282 (10000) ■ 0.01N hydrochloric acid in methanol 207 (18900), 250 (6600),
282 (9900) ■ 0.01 N sodium hydroxide in methanol 208 (19900), 245 (
9700), 281 (9600) 11) Infrared absorption spectrum. , xcm"-' Potassium bromide (KBr)
The infrared absorption spectrum measured by the tablet method is shown in FIG.
12)’H−核磁気共鳴スベクトル= (δ: pp
m)重メタノール中、500 MHzで測定した核磁気
共鳴スペクトルは第2図に示す通りである。12)'H-nuclear magnetic resonance vector = (δ: pp
m) The nuclear magnetic resonance spectrum measured at 500 MHz in heavy methanol is shown in FIG.
13)13C−核磁気共鳴スベクトル: (δ: p
pm)重メタノール中、125 MHzで測定した核磁
気共鳴スペクトルは第3図に示す通りである。13) 13C-nuclear magnetic resonance vector: (δ: p
pm) The nuclear magnetic resonance spectrum measured at 125 MHz in heavy methanol is shown in FIG.
12.0 (q)、 12.0 (q)、 16.5
((])、17、i (q)、 17.9 (q)、
23.4 (t)、23.4 (q)、 24.1 (
t)、 29.6 (t)、29.9 (t)、 32
.2 (t)、 33.6 (d)、36.7 (t)
、 37.4 (t)、 37.9 (t)、37.9
(d)、 39.2 (t)、 41.7 (t)、
43.7 (d)、 44.0 (d)、 45.0
(d)、48.2 (t)、 50.7 (t)、 5
4.5 (s)、57.6 (d)、 70.2 (d
)、 71.1 (d)、73.7 (d)、 75.
5 (d)、 77.6 (d)、78.3 (d)、
83.7 (d)、 103.0 (s)、120
.2 (d)、123.0 (d)、124.0 (d
)、129.8 (rJ)、134.3 (d)、13
4.3 (d)、135.0 (d)、139.7 (
s)、 140.4 (s)、141.1 (s)、1
55.8 (s)、igl、o (s)、192.3
(s)、204.0 (s)、本発明の新規物質CC1
2は種々の異性体を有する。前記式においては、これら
の異性体および異性体の混合物がすべて単一の式で示さ
れている。12.0 (q), 12.0 (q), 16.5
((]), 17, i (q), 17.9 (q),
23.4 (t), 23.4 (q), 24.1 (
t), 29.6 (t), 29.9 (t), 32
.. 2 (t), 33.6 (d), 36.7 (t)
, 37.4 (t), 37.9 (t), 37.9
(d), 39.2 (t), 41.7 (t),
43.7 (d), 44.0 (d), 45.0
(d), 48.2 (t), 50.7 (t), 5
4.5 (s), 57.6 (d), 70.2 (d
), 71.1 (d), 73.7 (d), 75.
5 (d), 77.6 (d), 78.3 (d),
83.7 (d), 103.0 (s), 120
.. 2 (d), 123.0 (d), 124.0 (d
), 129.8 (rJ), 134.3 (d), 13
4.3 (d), 135.0 (d), 139.7 (
s), 140.4 (s), 141.1 (s), 1
55.8 (s), igl, o (s), 192.3
(s), 204.0 (s), Novel substance of the present invention CC1
2 has various isomers. In the above formula, all these isomers and mixtures of isomers are represented by a single formula.
従って、本発明においてはこれらの異性体およびこれら
の異性体の混合物をもすべて含むものである。Therefore, the present invention includes all of these isomers and mixtures of these isomers.
本発明の新規物質CC12は、常法にしたがって塩とす
ることができる。そのような塩としては例えばリチウム
、ナトリウム、カリウムのようなアルカリ金属;カルシ
ウム、バリウムのようなアルカリ土類金属;アルミニウ
ム;またはリジン、アルギニンのような塩基性アミノ酸
;などの塩基:または塩酸、硫酸、リン酸、臭化水素酸
、硝酸のような無機酸;酢酸、シュウ酸、マレイン酸、
リンゴ酸、コハク酸、安息香酸のような有機酸;などの
酸:との塩をあげることができる。このような塩のうち
、好適には薬理上許容される塩である。The novel substance CC12 of the present invention can be converted into a salt according to a conventional method. Such salts include, for example, alkali metals such as lithium, sodium and potassium; alkaline earth metals such as calcium and barium; aluminum; or basic amino acids such as lysine and arginine; and bases such as hydrochloric acid and sulfuric acid. , phosphoric acid, hydrobromic acid, nitric acid; acetic acid, oxalic acid, maleic acid,
Examples include salts with organic acids such as malic acid, succinic acid, and benzoic acid; Among such salts, pharmacologically acceptable salts are preferred.
新規物質CC12の生産菌であるストレプトミセス・エ
スピーSANK 60390株は青森県下北郡大畑町で
採取した土壌から分離されたものであり、その菌学的性
状は次の通りである。Streptomyces sp. SANK 60390 strain, which is the producing bacterium of the new substance CC12, was isolated from soil collected in Ohata-cho, Shimokita-gun, Aomori Prefecture, and its mycological properties are as follows.
1、形態学的特徴
SANK 60390株は菌株同定用寒天培地上、28
℃、フないし14日間の培養において、比較的良好に生
育する。基生菌糸は良好に伸長、分岐し、薄黄味橙色を
示すが断裂やノカルデイア様のジグザグ伸長は観察され
ない。気菌糸は比較的良好に形成し、茶味白、明るい茶
味灰ないし、オリーブ灰色を示す。気菌糸の先端には1
0〜50個または50個以上の胞子鎖を形成し、螺旋状
を示す。胞子の表面は平滑状である。胞子柄の着生は気
菌糸上のみであり、胞子のう、べん毛胞子、菌核、車軸
分岐等の特殊器官は認められない。1. Morphological characteristics The SANK 60390 strain was grown on agar medium for strain identification, 28
It grows relatively well when cultured at ℃ for 14 days. The basal hyphae are well elongated and branched, showing a light yellowish-orange color, but no fractures or Nocardia-like zigzag elongation are observed. Aerial mycelium is relatively well formed and exhibits brownish white, light brownish gray, or olive gray color. 1 at the tip of aerial hyphae
Forms chains of 0 to 50 or more than 50 spores and exhibits a spiral shape. The surface of the spore is smooth. Spore stalks are only attached to aerial hyphae, and special organs such as sporangia, flagellar spores, sclerotia, and axle branches are not observed.
2、各種培養基上の諸性質
各種培養基上で28℃、14日間培養後の性状は次表に
示した通りである。色調の表示は日本色彩研究新版″標
準色表″のカラーチップ・ナンバーをあられす。2. Properties on various culture media The properties after culturing on various culture media at 28°C for 14 days are as shown in the following table. Color tones are indicated using the color chip numbers of the Japan Color Research New Edition ``Standard Color Table''.
シュクロース・
硝酸塩寒天
G:
へMニ
ゲルコース・
アスパラギン
寒天
R:
SP二
G=
八M:
R:
SP二
G:
グリセリン・
アスパラギン
寒天(ISP 5) AM :
R:
良好、平坦、薄黄味橙
余り良くない、ビロード
状、明るい茶味白
4黄法条(4−8−9)
産生ぜず
良好、平坦、薄黄味橙
僅かに形成、白
4黄法条(4−8−8)
産生ぜず
非常に良好、平坦、薄黄
法条(4−8−9)
良好に形成、ビロード状、
4黄法条(2−7−9)
4黄法条(6−8−9)
澱粉・
無機塩寒天
(ISP 4)
チロシン寒天
(ISP 7)
栄養寒天
(DIFCO)
G: 良好、平坦、4黄法条
八M: 良好に形成、ビロード状、
茶味白(1−6−6)
R: 4黄法条(6−8−9)
SP: 産生せず
G: 非常に良好、平坦、薄黄
法条(4−8−9)
八M: 良好に形成、ビロード状、
4黄法条(2−7−9)
R: 4黄法条(6−8−9)
SP: 産生せず
G: 良好、平坦、薄黄味橙
へM二 余り良くない、ビロード
状、白
R: 4黄法条(4−8−9)
イーストエキ Gニ
ス・麦芽エキス
寒天(ISP 2) AM :
オートミール
寒天(ISP 3)
R:
SP二
G :
八M:
R:
SP:
水寒天
G:
八M:
R:
非常に良好、平坦、
4黄法条(4−8−9)
豊富に形成、ビロード状、
オリーブ灰(1−6−10)
黄法条(8−7−9)
産生ぜず
良好、平坦、4黄法条
豊富に形成、ビロード状、
茶味白(1−6−6)
4黄法条(4−7−10)
産生ぜず
良くない、平坦、薄黄味
橙(2−9−9)
僅かに形成、明るい茶味
灰(2−7−8)
明るい茶味灰(2−8−8)
ポテトエキス・ G: 余り良くない、平坦、人参エキ
ス寒天 薄黄味橙(2−9−9)AM: 良好、
ビロード状、灰味
茶(4−5−6)
R: 4黄法条(2−7−9)
SP: 産生せず
G:生育、 AM:気菌糸、
R:裏面、 SP:可溶性色素
3、生理学的性質
28℃で培養後、2ないし21日間に観察したSANK
60390株の生理学的性質は次表に示したとうりで
ある。Sucrose/Nitrate Agar G: HeM Gelcose/Asparagine Agar R: SP2G=8M: R: SP2G: Glycerin/Asparagine Agar (ISP 5) AM: R: Good, flat, pale yellowish orange. Not good, velvety, light brownish white 4-Kohashi (4-8-9) Good quality, flat, pale yellowish orange, slightly formed, white 4-Kohashi (4-8-8) Very good, flat, pale yellow stripes (4-8-9) Well formed, velvety, 4 yellow stripes (2-7-9) 4 yellow stripes (6-8-9) Starch/inorganic salts Agar (ISP 4) Tyrosine Agar (ISP 7) Nutrient Agar (DIFCO) G: Good, flat, 4 yellows M: Well formed, velvety, brownish white (1-6-6) R: 4 yellows (6-8-9) SP: Not produced G: Very good, flat, pale yellow stripes (4-8-9) 8M: Well formed, velvety, 4 yellow stripes (2-7 -9) R: 4 yellow stripes (6-8-9) SP: No production G: Good, flat, pale yellowish orange M2 Not so good, velvety, white R: 4 yellow stripes (4 -8-9) Yeast extract G varnish/malt extract agar (ISP 2) AM: Oatmeal agar (ISP 3) R: SP2G: 8M: R: SP: Water agar G: 8M: R: Very good , flat, 4 yellow stripes (4-8-9) abundantly formed, velvety, olive ash (1-6-10) yellow stripes (8-7-9) good production, flat, 4 yellow stripes Richly formed, velvety, brown-white (1-6-6) 4 yellow-colored stripes (4-7-10) Poorly formed, flat, pale yellowish-orange (2-9-9) Slightly formed , Light brownish gray (2-7-8) Light brownish gray (2-8-8) Potato extract G: Not very good, flat, Carrot extract agar Light yellowish orange (2-9-9) AM: Good,
Velvety, gray brown (4-5-6) R: 4 Yellow Laws (2-7-9) SP: No production G: Growth, AM: Aerial mycelium, R: Back side, SP: Soluble pigment 3, Physiological properties SANK observed for 2 to 21 days after culturing at 28°C
The physiological properties of strain 60390 are shown in the table below.
澱粉の氷解 陽 性ゼラチン
の液化 陽 性硝酸塩の還元
陽 性ミルクの凝固
陽 性ミルクのペプトン化
陽 性メラニン様色素生産性(培地1)* 陰
性(培地2)木 陰 性
カゼイン 陰 性
チロシン 陽 性
キサンチン 陽 性
生育温度範囲(培地3)* 15〜36℃
食塩耐性 7%*:培地1
;トリプトン・イーストエキス・ブロス(ISP 1)
2;チロシン寒天(ISP 7)
3;イーストエキス・麦芽エキス寒天
(ISP 2)
また、プリドハム・ゴトリーブ寒天培地(ISP9)を
使用して、28℃、14日間培養後に観察したSANK
60390株の炭素源の資化性は次表に示すとうりで
ある。Deicing of starch Liquefaction of positive gelatin Reduction of positive nitrate
Coagulation of positive milk
Peptonization of positive milk
Positive Melanin-like pigment production (medium 1) * Negative
Growth temperature range (Medium 3)* 15-36℃
Salt tolerance 7%*: Medium 1
Tryptone Yeast Extract Broth (ISP 1) 2 Tyrosine Agar (ISP 7) 3 Yeast Extract Malt Extract Agar (ISP 2) Also, using Pridham-Gotlieb agar medium (ISP 9), 28°C, 14 SANK observed after one day of culture
The carbon source assimilation ability of the 60390 strain is shown in the table below.
D−グルコース + D−フルクトース ±L−ア
ラビノース + L−ラムノース ±D−キシロー
ス 士 シュクロース +イノシトール
士 ラフィノース +D−マンニトール −
対 照
基質分解性
SANK 60390株の細胞壁はビー・ペソカーらの
方法[B、 Becker et al、、 Appl
ied Microbiology。D-glucose + D-fructose ±L-arabinose + L-rhamnose ±D-xylose Sucrose + inositol
Raffinose + D-Mannitol -
The cell wall of the control substrate-degrading SANK 60390 strain was prepared using the method of Becker et al. [B, Becker et al., Appl.
ied Microbiology.
12巻、421〜423頁、1984年〕に従い検討し
た結果、LL−ジアミノピメリン酸およびグリシンが検
出されたことから、細胞壁タイプ■型であることが確認
された。また、SANK 60390株の全細胞壁中の
糖成分をエム・ピー・レシエバリエの方法[M、 P、
Lechevalier、 Journal of
Laboratory& C11nical Medi
cine、 71巻、834頁、1968年]に従い検
討した結果、特徴的なパターンは認められなかった。12, pp. 421-423, 1984], LL-diaminopimelic acid and glycine were detected, and it was confirmed that the cell wall type was type II. In addition, the sugar components in the whole cell wall of SANK 60390 strain were analyzed using the M.P.
Lechevalier, Journal of
Laboratory & C11nical Medi
cine, Vol. 71, p. 834, 1968], no characteristic pattern was observed.
以上のことから、本菌株は放線菌の中でもストレプトミ
セス属に属することが判明したので、ストレプトミセス
0エスピー(Streptomyces sp+)S
ANK 60390 (微工研菌寄第11523号;
FERM P11523 )と命名された。From the above, it was found that this bacterial strain belongs to the genus Streptomyces among actinomycetes, and therefore, it is classified as Streptomyces sp+.
ANK 60390 (Microtechnology Research Institute No. 11523;
FERM P11523).
なお、SANK 60390株の同定はISP Cジ・
インターナショナル・ストレプトミセス・プロジェクト
(The International Strept
omyces Project)〕基準、バーシーズ・
マニュアル(Bergey s Manual of
Systematic Bacteriology)第
4巻、ジ・アクチノミセテス(The Actinom
ycetes)第2巻および放線菌に関する最近の文献
によって行った。The SANK 60390 strain was identified by ISP C Di.
The International Streptomyces Project
omyces Project) Standards, Bersey's
Bergey's Manual of
Systematic Bacteriology Volume 4, The Actinomycetes
ycetes) Volume 2 and recent literature on actinomycetes.
以上、CC12の生産菌について説明したが、放線菌の
諸性質は一定したものではなく、自然的、人工的に容易
に変化することは周知の通りであり、本発明で使用しう
る菌株は、ストレプトミセス属に属するCC12を生産
するすべての菌株を包含するものである。The bacteria that produce CC12 have been explained above, but it is well known that the properties of actinomycetes are not constant and can easily change naturally or artificially, and the strains that can be used in the present invention include: This includes all strains that produce CC12 belonging to the genus Streptomyces.
本発明の新規化合物CC12は、ストレプトミセス属に
属するCC12生産菌を適当な培地で好気的に培養し、
培養物から目的物を採取することによって製造すること
ができる。The novel compound CC12 of the present invention can be obtained by aerobically culturing CC12-producing bacteria belonging to the genus Streptomyces in an appropriate medium.
It can be produced by collecting the target product from a culture.
培地は、CC12生産菌が利用しうる任意の栄養源を含
有するものでありうる。具体的には、例えば、炭素源と
してグルコース、シュークロース、マルトース、スター
チおよび油脂類などが使用でき、窒素源として大豆粉、
綿実粕、乾燥酵母、酵母エキスおよびコーンステイープ
リカーなどの有機物ならびにアンモニウム塩または硝酸
塩、たとえば硫酸アンモニウム、硝酸ナトリウムおよび
塩化アンモニウムなどの無機物が利用できる。また、必
要に応じて、塩化ナトリウム、塩化カリウム、燐酸塩、
重金属塩など無機塩類を添加することができる。発酵中
の発泡を抑制するために、常法に従って適当な消泡剤、
例えばシリコン油を添加することもできる。The medium can contain any nutrient source that can be utilized by the CC12-producing bacteria. Specifically, for example, glucose, sucrose, maltose, starch, fats and oils can be used as carbon sources, and soybean flour, soybean flour and nitrogen can be used as nitrogen sources.
Organic materials such as cottonseed meal, dried yeast, yeast extract and corn staple liquor and inorganic materials such as ammonium salts or nitrates such as ammonium sulfate, sodium nitrate and ammonium chloride can be utilized. In addition, sodium chloride, potassium chloride, phosphate,
Inorganic salts such as heavy metal salts can be added. In order to suppress foaming during fermentation, a suitable antifoaming agent,
For example, silicone oil can also be added.
培養方法としては、一般に行われている抗生物質の生産
方法と同じく、好気的液体培養法が最も適している。培
養温度は20−37℃が適当であるが、25−30℃が
好ましい。この方法でCC12の生産量は、振盪培養、
通気攪拌培養ともに培養4日間で最高に達する。The most suitable culture method is the aerobic liquid culture method, which is the same as the commonly used antibiotic production method. The culture temperature is suitably 20-37°C, preferably 25-30°C. In this method, the production amount of CC12 can be determined by shaking culture,
Both the aeration and agitation culture reached the maximum after 4 days of culture.
このようにしてCC12の蓄積された培養物が得られる
。培養物中では、CC12はその一部は菌体中に存在す
るが、その大部分は培養濾液中に存在する。In this way an enriched culture of CC12 is obtained. In the culture, a portion of CC12 exists in the bacterial cells, but most of it exists in the culture filtrate.
このような培養物からCC12を採取するには、合目的
的な任意の方法が利用可能である。そのひとつの方法は
抽出の原理に基くものであって、具体的には、培養ろ液
中のCC12についてはこれを水不混和性のCC12用
溶媒、例えばブタノールなどで抽出する方法、あるいは
菌体内のCC12についてはろ過、遠心分離などで得た
菌体集体をメタノール、エタノール、アセトンなどで処
理して回収する方法などがある。菌体を分離せずに培養
物そのままを上記の抽出操作に付すこともできる。適当
な溶媒を用いた向流分配法も抽出の範晴に入れることが
できる。Any convenient method can be used to harvest CC12 from such cultures. One method is based on the principle of extraction, and specifically, for CC12 in the culture filtrate, it can be extracted with a water-immiscible solvent for CC12, such as butanol, or Regarding CC12, there is a method of recovering bacterial cell aggregates obtained by filtration, centrifugation, etc., by treating them with methanol, ethanol, acetone, etc. The culture itself can also be subjected to the above extraction operation without separating the bacterial cells. Countercurrent distribution methods using suitable solvents can also be included in the scope of extraction.
培養物からCC12を採取する他のひとつの方法は吸着
の原理に基くものであって、既に液状となっているCC
12含有物、たとえば培養ろ液あるいは上記のようにし
て抽出操作を行うことによって得られる抽出液を対象と
して、適当な吸着剤、たとえばシリカゲル、活性炭、「
ダイヤイオンHP20J (商品名、三菱化成曲社製
)などを用いて目的のCC12を吸着させ、その後、適
当な溶媒にて溶離させることによってCC12を得るこ
とができる。このようにして得られたCC12溶液を減
圧濃縮乾固すれば、CC12粗標品が得られる。Another method for collecting CC12 from cultures is based on the principle of adsorption, in which CC12 is already in liquid form.
12-containing substances, such as culture filtrate or the extract obtained by performing the extraction operation as described above, using a suitable adsorbent such as silica gel, activated carbon, etc.
CC12 can be obtained by adsorbing the target CC12 using Diaion HP20J (trade name, manufactured by Mitsubishi Kaseikyoku Co., Ltd.) or the like, and then eluting it with an appropriate solvent. The CC12 solution thus obtained is concentrated to dryness under reduced pressure to obtain a crude sample of CC12.
このようにして得られるCC12の粗標品をさらに精製
するためには、上記の抽出法および吸着法にゲルろ適法
、高速液体クロマトグラフィーなどを必要に応じて組合
せて必要回数行えばよい。In order to further purify the crude sample of CC12 obtained in this way, the extraction method and adsorption method described above may be combined with a gel filtration method, high performance liquid chromatography, etc. as necessary, and the procedure may be performed as many times as necessary.
例えば、シリカゲルなどの吸着剤、[セファデックスL
H−204(商品名、ファルマシア社製)などのゲルろ
通則を用いたカラムクロマトグラフィ゛、rYMCパッ
クj (商品名、山村科学社製)などを用いた高速液体
クロマトグラフィーおよび向流分配法を適宜組合せて実
施することができる。For example, adsorbents such as silica gel, [Sephadex L
Column chromatography using gel filtration rules such as H-204 (trade name, manufactured by Pharmacia), high-performance liquid chromatography using rYMC pack j (trade name, manufactured by Yamamura Kagaku Co., Ltd.), and countercurrent distribution method as appropriate. Can be implemented in combination.
具体的には、例えば、CC12粗標品を[セファデック
スLH−2OJカラムにイ寸し、メタノールで活性画分
を溶出させ、濃縮乾固するとCC12の純品が得られる
。Specifically, for example, a crude sample of CC12 is placed in a Sephadex LH-2OJ column, the active fraction is eluted with methanol, and concentrated to dryness to obtain a pure product of CC12.
本発明のCC12は、文献未載の新規物質であり、動物
(例、ヒト、イヌ、ネコ、ウサギ等)に対して抗菌活性
を有し、抗菌剤として有用である。CC12 of the present invention is a novel substance that has not been described in any literature, has antibacterial activity against animals (eg, humans, dogs, cats, rabbits, etc.) and is useful as an antibacterial agent.
したがって、本発明物質は抗菌剤もしくは感染症治療剤
として使用することができる。Therefore, the substance of the present invention can be used as an antibacterial agent or a therapeutic agent for infectious diseases.
抗菌剤としての本発明物質は合目的的な任意の投与経路
で、また採用投与経路によって決る剤型、例えば粉末、
顆粒、錠剤、カプセル剤、注射剤などの形態、で経口的
または非経口的に安全に投与することができる。薬剤と
しては、製薬上許容される担体あるいは希釈剤で希釈さ
れた形態が普通である。The substances of the invention as antibacterial agents can be administered by any convenient route of administration and in the form determined by the route of administration employed, such as powder,
It can be safely administered orally or parenterally in the form of granules, tablets, capsules, injections, and the like. The drug is usually in a diluted form with a pharmaceutically acceptable carrier or diluent.
本発明の物質を医薬として投与する場合、これを注射用
蒸留水または生理食塩水に溶解して注射する方法が代表
的なもののひとつとして挙げられる。具体的には、腹腔
内注射、皮下注射、静脈または動脈への血管内注射およ
び注射による局所投与などの方法がある。When administering the substance of the present invention as a medicine, one typical method is to dissolve it in distilled water for injection or physiological saline and inject it. Specifically, methods include intraperitoneal injection, subcutaneous injection, intravascular injection into a vein or artery, and local administration by injection.
本発明物質の投与量は、動物試験の結果および種々の状
況を勘案して、連続的または間欠的に投与したときに総
投与量が一定量を越えないように定められる。具体的な
投与量は、投与方法、患者または被処理動物の状況、た
とえば年齢、体重、性別、感受性、食餌、投与時間、併
用する薬剤、患者またはその病気の程度に応じて異なる
が、例えば、成人1日あたり0.01〜5gを、症状に
応じて1回または数回に分けて投与するのが好ましい。The dosage of the substance of the present invention is determined in consideration of the results of animal tests and various situations so that the total dosage does not exceed a certain amount when administered continuously or intermittently. The specific dosage varies depending on the administration method, the situation of the patient or treated animal, such as age, weight, sex, sensitivity, diet, administration time, concomitant drugs, and the degree of the patient or his/her disease, but for example, It is preferable to administer 0.01 to 5 g per day for adults, once or in divided doses, depending on the symptoms.
(実施例)
次に実施例および試験例をあげて本発明をさらに具体的
に説明する。(Example) Next, the present invention will be explained in more detail by giving examples and test examples.
実施例1.新規物質CC12の生産
1)培養
使用した培地は、下記の組成の成分をILの水に溶解し
て、pH7,0に調整したものである。Example 1. Production of novel substance CC12 1) Culture The medium used was one in which components having the following composition were dissolved in IL water and adjusted to pH 7.0.
培地組成
グリセリン 20 g
モラセス 10 g
カゼイン 5g
ポリペプトン 1g
炭酸カルシウム 4g
上記培地を100 mlずつ500 ml容イボ付三角
フラスコに分注殺菌したものへ、ストレプトミセス・エ
スピーSANK 60390株を接種し、27℃にて4
日間、200 rpmの回転培養を行った。Medium composition Glycerin 20 g Molasses 10 g Casein 5 g Polypeptone 1 g Calcium carbonate 4 g 100 ml of the above medium was dispensed into sterilized Erlenmeyer flasks with warts, inoculated with Streptomyces sp. SANK 60390 strain, and heated to 27°C. Te4
Rotational culture was performed at 200 rpm for 1 day.
2)単離
上記の条件で培養後、培養液2Lをろ過し、ろ液をダイ
アイオンHP20 (商品名、三菱化成■社製)カラム
(3cmφX 25 cm)に吸着させた。カラムを5
0%メタノールで洗浄後、50%アセトン500 ml
で溶出し、溶出液をZOOmlまで濃縮した。これを2
00 mlのブタノールで3回抽出し、濃縮後、シリカ
ゲル(商品名「ワコーゲルC200J 、和光純薬工業
■社製)カラム(2cmφx 20 cm)に付し、ク
ロロホルム−メタノール−29%アンモニア水(5:3
:1)で展開した。活性フラクションを濃縮して得られ
た CC12の粗粉末を少量のメタノールに溶解し、セ
ファデックスLH−20カラム(ファルマシア社製)(
2,50mφX 50 cm)中、メタノールでクロマ
トグラフィーを行なった。活性画分を濃縮乾固すること
により、28 mgのCC12の純品が得られた。2) Isolation After culturing under the above conditions, 2 L of the culture solution was filtered, and the filtrate was adsorbed onto a Diaion HP20 (trade name, manufactured by Mitsubishi Kasei Corporation) column (3 cmφ x 25 cm). column 5
After washing with 0% methanol, 500 ml of 50% acetone
The eluate was concentrated to ZOOml. This 2
Extracted three times with 00 ml of butanol, concentrated, applied to a silica gel (trade name: Wako Gel C200J, manufactured by Wako Pure Chemical Industries, Ltd.) column (2 cm φ x 20 cm), and extracted with chloroform-methanol-29% aqueous ammonia (5: 3
:1). The crude powder of CC12 obtained by concentrating the active fraction was dissolved in a small amount of methanol and applied to a Sephadex LH-20 column (manufactured by Pharmacia) (
Chromatography was performed using methanol in a vacuum chamber (2,50 mφ x 50 cm). By concentrating the active fraction to dryness, 28 mg of pure CC12 was obtained.
試験例1.抗菌スペクトル
一般細菌に対するCC12の最小発育阻止濃度は普通寒
天培地(栄研化学■製)、カビに対してはサブロー寒天
培地(栄研化学■製)を用いて寒天培地希釈法によって
測定した。Test example 1. Antibacterial Spectrum The minimum inhibitory concentration of CC12 against general bacteria was measured by the agar medium dilution method using ordinary agar medium (manufactured by Eiken Kagaku ■) and Sabouraud agar medium (manufactured by Eiken Kagaku ■) for fungi.
スタフィロコッカス・7ウレウス 209PスタフイD
コツカス・7ウレウス 56Rスタフイ■ゴツがス・ア
ウレウス 535(MR3A)エンテU]ツカス・フェ
カリス 681エスシエリシ7・コリー NIHJ
エスシェリシ7・コリー 609
クレフ”シェラ・二1モニエ 806
7°ロチウス・7゛ルh゛クス 1420シユードモナ
ス・エルキ゛ノーサ 1001キヤンシ゛り゛・フルヒ
゛カンス SCクリプトコツカス・ネtフtルマンス
580637スベル〜゛ルス・フミカ゛タス
10569トリコフイトン・メンタク°゛■フイテ
ス SC3,1
6,2
6,2
〉100
〉200
〉200
〉200
>200
〉200
〉50
>50
〉50
(発明の効果)
このように、本発明の新規物質CC1−2は、細菌、特
にダラム陽性菌に対して抗菌作用を示し、抗菌剤として
有用である。Staphylococcus 7 ureus 209P Staphyi D
Kotsukas 7 Uraeus 56R Staphyi ■Gotsugasu Aureus 535 (MR3A) EnteU] Tucas faecalis 681 Escherisi 7 Collie NIHJ Escherisi 7 Collie 609 Clef” Shera 21 Monier 806 7° Lotius 7゛elh゛1420 Pseudomonas ercinosa 1001 Cancellus fluhicans SC Cryptococcus netrumans
580637 Suberus fumicatus
10569 Trichophyton mentacus °゛■Phytes SC3,1 6,2 6,2 〉100 〉200 〉200 〉200 〉200 〉200 〉50 〉50 〉50 (Effect of the invention) In this way, the novel substance CC1 of the present invention -2 exhibits antibacterial activity against bacteria, particularly Durham-positive bacteria, and is useful as an antibacterial agent.
第1図は、CC12の赤外吸収スペクトルを示す。
第2図は、同物質の1H−核磁気共鳴スペクトルを示す
。
第3図は、同物質の13C−核磁気共鳴スペクトルを示
す。FIG. 1 shows the infrared absorption spectrum of CC12. FIG. 2 shows the 1H-nuclear magnetic resonance spectrum of the same substance. FIG. 3 shows the 13C-nuclear magnetic resonance spectrum of the same substance.
Claims (1)
し、その培養物よりCC12を採取することを特徴とす
るCC12の製造法。 3、請求項2、において、ストレプトミセス属に属する
CC12生産菌がストレプトミセス・エスピーSANK
60390株(微工研菌寄第11523号;FERMP
−11523)である製造法。[Claims] 1. A novel substance CC12 represented by the following formula and a salt thereof. ▲There are mathematical formulas, chemical formulas, tables, etc.▼ 2. A method for producing CC12, which is characterized by culturing CC12-producing bacteria belonging to the genus Streptomyces and collecting CC12 from the culture. 3. In claim 2, the CC12-producing bacterium belonging to the genus Streptomyces is Streptomyces sp.
60390 strain (FERMP No. 11523; FERMP
-11523).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16066690A JPH0645593B2 (en) | 1990-06-19 | 1990-06-19 | New substance CC12 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16066690A JPH0645593B2 (en) | 1990-06-19 | 1990-06-19 | New substance CC12 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0449277A true JPH0449277A (en) | 1992-02-18 |
JPH0645593B2 JPH0645593B2 (en) | 1994-06-15 |
Family
ID=15719864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16066690A Expired - Lifetime JPH0645593B2 (en) | 1990-06-19 | 1990-06-19 | New substance CC12 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0645593B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496619A (en) * | 1992-05-14 | 1996-03-05 | Matsushita Electric Industrial Co., Ltd. | Assembly formed from conductive paste and insulating paste |
US5863581A (en) * | 1996-04-25 | 1999-01-26 | Lipton, Division Of Conopco, Inc. | Tea processing with zeolites |
-
1990
- 1990-06-19 JP JP16066690A patent/JPH0645593B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496619A (en) * | 1992-05-14 | 1996-03-05 | Matsushita Electric Industrial Co., Ltd. | Assembly formed from conductive paste and insulating paste |
US5863581A (en) * | 1996-04-25 | 1999-01-26 | Lipton, Division Of Conopco, Inc. | Tea processing with zeolites |
Also Published As
Publication number | Publication date |
---|---|
JPH0645593B2 (en) | 1994-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU716524A3 (en) | Method of preparing substances possessing antiparasitic activity | |
JPH02288837A (en) | Method for inhibiting pneumocystis carinii | |
JPS5910798B2 (en) | New method for producing rifamycins | |
JPS6276A (en) | Enzyme-inhibiting novel substance | |
JPH0449277A (en) | Novel substance cc12 | |
JPH03141290A (en) | Antitumor antibiotic BMY-41339 | |
WO1999032498A1 (en) | Antibiotic tkr2999, process for the preparation thereof and microbe | |
JPS61145145A (en) | Anthracycline derivatives and their microbiological preparation | |
JPS60156392A (en) | Fr-900336 substance and its preparation | |
JPH02221292A (en) | New substance 02-3, its use and production thereof | |
JPS60218396A (en) | Antibiotic do-248-a and do-248-b and preparation thereof | |
JPH03232887A (en) | New substance bk 97, use thereof and production thereof | |
JPH01290673A (en) | Novel substance k3543r1, its use and production | |
JPH0585998A (en) | New compounds ca39-a and ca39-b, their use and production | |
JPH0259596A (en) | Novel substance, utilization and production thereof | |
JPH05202089A (en) | Antibiotic ll-e19020 alpha 1 | |
JPH02167092A (en) | Anti-tumor agent containing lisolipin x and production of lisolipin x | |
JPH02286683A (en) | Novel substance dt136 and its production | |
JPS63203695A (en) | Novel substance k818 | |
JPH03191788A (en) | Novel antibiotic substance nk155141 and its production | |
JPH09208585A (en) | New physiologically active substance qm16-a, its use and production thereof | |
JPS6281398A (en) | Anthracycline compound and use thereof | |
JPS62138196A (en) | Anthracyclin compound and production thereon | |
JPH0383980A (en) | Novel antibiotic substance 10'-demethoxystrepto-nigrin | |
JPH03218341A (en) | Novel antibiotic nk 372135, its production and its use |